Literature DB >> 8053717

Melanoma risk in individuals with clinically atypical nevi.

S Kang1, R L Barnhill, M C Mihm, T B Fitzpatrick, A J Sober.   

Abstract

BACKGROUND AND
DESIGN: A lack of consensus as to the clinical and histologic characteristics of dysplastic nevi has resulted in the recommendation to abandon the term dysplastic nevus for the more descriptive atypical nevus or atypical mole. The significance of the presence of one or more such lesions, histologic features notwithstanding, has not been carefully examined. The risk of melanoma was assessed in individuals with atypical nevi monitored regularly in our Pigmented Lesion Clinic. Any patient enrolled in this subspecialty clinic between 1980 and 1985 without the diagnosis of melanoma who had at least one sufficiently atypical-appearing nevus and who was followed up for a minimum of 5 years was entered in the study.
RESULTS: A total of 155 such individuals were identified. The mean (+/- SEM) age of the patients at first evaluation was 26 +/- 1 years. The group was followed for 7 +/- 1 years. The male-female ratio was 1:1. A family history of melanoma was present in 71 subjects (46%). Of the 155 patients, two developed melanoma. The thickness of the tumors in both patients was less than or equal to 0.8 mm. Twenty-five patients (16%), including the two with melanoma, had at least one nevus removed that showed "severe nuclear atypia."
CONCLUSIONS: The risk of melanoma in individuals with atypical nevi is significantly greater than expected. The elevated risk was demonstrated even though careful, regular evaluations and removal of more atypical lesions were performed. This study provides evidence that, compared with no surveillance, the meticulous monitoring of patients with clinically atypical nevi is more likely to result in the detection of melanoma at thin stages, with an attendant improved prognosis.

Entities:  

Mesh:

Year:  1994        PMID: 8053717

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  3 in total

1.  Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Authors:  Shawn Tahata; Shivendra V Singh; Yan Lin; Eun-Ryeong Hahm; Jan H Beumer; Susan M Christner; Uma N Rao; Cindy Sander; Ahmad A Tarhini; Hussein Tawbi; Laura K Ferris; Melissa Wilson; Amy Rose; Catherine M Dietz; Ellen Hughes; Jed W Fahey; Sancy A Leachman; Pamela B Cassidy; Lisa H Butterfield; Hassane M Zarour; John M Kirkwood
Journal:  Cancer Prev Res (Phila)       Date:  2018-04-24

2.  α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.

Authors:  M Abbas; E M Ploch; J Wehling; E Schipper; S Janciauskiene; H H Kreipe; D Jonigk
Journal:  Tumour Biol       Date:  2014-08-24

3.  Awareness, knowledge, and attitudes towards sun protection among patients with melanoma and atypical mole syndrome.

Authors:  Dimitra Koumaki; Marios Papadakis; Stamatoula Kouloumvakou; Konstantinos Krasagakis
Journal:  World J Clin Oncol       Date:  2022-07-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.